Edwards to supply Interpore's AGF (autologous growth factor) products:
This article was originally published in Clinica
Edwards Lifesciences Cardiovascular Resources is to supply Interpore Cross' autologous growth factor (AGF) related products to US hospitals where it provides contract perfusion and autotransfusion services. AGF is a concentrate of growth factors that enhances bone growth and healing derived from the patient's blood. The companies, both based in Irvine, California, did not reveal financial details of the three-year, exclusive agreement. David Mercer, CEO of Interpore Cross, said: "While we continue to focus on bone grafting procedures, we believe Edwards' leading position in the market for perfusion and autotransfusion services may also help us gain exposure to a variety of wound healing applications."
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.